FB78R2c2, CENSOi249
CENSOi001-B
General
Cell Line |
|
hPSCreg name | CENSOi001-B |
Cite as: | CENSOi001-B (RRID:CVCL_LE86) |
Alternative name(s) |
FB78R2c2, CENSOi249
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
CENSOi003-B (FB79R2c6, CENSOi258) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi005-A (FB76R2c5, CENSOi245) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi007-A (FB75R2c5, CENSOi255) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi002-B (FB74R2c4, CENSOi261) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi008-A (FB77R2c3, CENSOi260) Donor's gene variants: DMPK, DMPK Donor diseases: myotonic dystrophy type 1 RCi009-A (Rci201, FB73c6) Donor's gene variants: LRIF1, LRIF1 Donor diseases: Facioscapulohumeral dystrophy RCi006-A (FB69c4, RCi169) Donor's gene variants: LRIF1, LRIF1 Donor diseases: Facioscapulohumeral dystrophy RCi007-A (FB70c1, RCi170) Donor's gene variants: LRIF1, LRIF1 Donor diseases: Facioscapulohumeral dystrophy STBCi110-A (SFC116-03-01) Donor's gene variants: CFH Donor diseases: type 2 diabetes mellitus age-related macular degeneration |
Last update | 14th May 2022 |
User feedback | |
Provider |
|
Generator | Censo an Axol Bioscience Company (CENSO) |
Distributors | |
External Databases |
|
BioSamples | SAMEA104133950 |
Cellosaurus | CVCL_LE86 |
Wikidata | Q54809293 |
General Information |
|
Publications |
|
Projects | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
Sex | male |
Age of donor (at collection) | 5-9 |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Disease associated phenotypes |
|
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
No
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA104133951 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Please provide the contact information | Dr Joana Domingos |
Is there other documentation provided to the donor for consenting purposes? | No |
Confirm that consent was obtained by a qualified professional | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent pertain to a specific research project? | Yes |
Details on restriction to research project | research area restriction to Neuromuscular Research |
Does consent permit unforeseen future research, without further consent? | Yes |
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
Does consent expressly prevent development of commercial products? | No |
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
a public organisation? | Yes |
a non-profit company? | Yes |
a for-profit corporation? | Yes |
How may genetic information associated with the cell line be accessed? | No information |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
Does consent permit access to medical records of the donor? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | The London -West London & GTAC Research Ethics Committee |
Approval number | |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | The London -West London & GTAC Research Ethics Committee |
Approval number | |
Do you have obligations to third parties in regard to the use of the cell line? | Yes |
Please describe: | research area restriction to Neuromuscular Research |
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
Source cell type |
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
|
Age of donor (at collection) | 5-9 |
Collected in | 2011 |
Passage number reprogrammed | 5 |
Reprogramming method |
|
Vector type | None |
Vector free reprogramming |
|
Type of used vector free reprogramming factor(s) |
mRNA
|
mRNA | |
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
O2 Concentration | 21 % |
CO2 Concentration | 5 % |
Medium |
mTeSR™ 1
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
TRA 1-60 |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
||||
SSEA-1 |
No |
|
||||
SSEA-4 |
Yes |
|
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Certificate of Analysis |
|
Is there a certificate of analysis available? |
Yes
Passage:
10
|
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
46,XY
Passage number: 12
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.